Objectives
• This analysis aimed to assess the costs and patient outcomes of parecoxib used in combination with opioids versus use of opioids alone in the postoperative treatment of surgical patients in China from the perspective of the third party payer.
Methods
• A decision analytic model, with a time horizon of 5 days postsurgery, was used to assess differences between parecoxib plus standard opioid therapy, and standard opioid therapy alone, in terms of clinical outcomes, resource utilisation due to postoperative opioid-related clinically meaningful events (CMEs*) and costs. In the model the choice of analgesic medication influences pain intensity and supplemental opioid use; opioid use determines the frequency of CMEs; while all of the above influence resource use and costs (see Figure1).
• Clinical efficacy was based on a Phase III, randomized, doubleblind, clinical trial that also provided the frequencies of individually and simultaneously occurring CMEs related to opioid use for both treatment arms (Nussmeier et al., 2006) . Resource use information is scarce in China, therefore a panel of clinical experts were interviewed to estimate additional resources use of the treatment of CMEs and the impact of having multiple CMEs at the same time through a resource-specific ratio of the length of use summed for different CMEs in separate patients versus length of use for multiple CMEs occurring in the same patient at the same time. Unit costs of ICU stay, general ward stay, physician and nurse time were estimated based on China Health Insurance Research Association database. The unit costs of other items were obtained from the same experts. Treatment outcome was calculated using summed pain intensity scores.
• A series of one-way sensitivity analyses were performed to test the robustness of the results (Figure2). *CMEs: adverse events with high frequency, moderate-high severity, or that are quite a bit/very much bothersome.
Results
• Patients treated with parecoxib plus opioids had lower summed pain intensity scores (87.20 vs 118.50) (Table 1 ) and fewer CMEs (0.87 vs 1.44 ) per patient (Table 2 ) compared with opioids alone for a 5-day post-operative period.
• This outcome led to a full offset of the excess cost of the addition of parecoxib and led to potential savings of ¥327.59 per patient compared with opioid use alone (Table 3) . Savings were mainly attributable to reduced resource use due to decreased CMEs (Table  4 ).
• Inter-clinician variability in the resource use estimates were high, but did not change the qualitative conclusions of the analyses. 
Conclusions
• Despite of relatively lower unit costs of resources use e.g. general ward stay and physician time in China, parecoxib used on top of opioids was a dominant strategy of postsurgical pain management by controlling pain intensity more effectively while reducing opioid-related CMEs, and lowering per-patient treatment costs.
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